AR013308A1 - Metodos para seleccionar compuestos utiles en la regulacion del peso corporal - Google Patents

Metodos para seleccionar compuestos utiles en la regulacion del peso corporal

Info

Publication number
AR013308A1
AR013308A1 ARP970102540A ARP970102540A AR013308A1 AR 013308 A1 AR013308 A1 AR 013308A1 AR P970102540 A ARP970102540 A AR P970102540A AR P970102540 A ARP970102540 A AR P970102540A AR 013308 A1 AR013308 A1 AR 013308A1
Authority
AR
Argentina
Prior art keywords
body weight
regulation
methods
useful compounds
selecting useful
Prior art date
Application number
ARP970102540A
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013308(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/662,560 external-priority patent/US5908609A/en
Priority claimed from US08/780,749 external-priority patent/US5932779A/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR013308A1 publication Critical patent/AR013308A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invencion se refiere a ensayos para la seleccion de drogas, y a métodos de diagnostico y terapéutica para eltratamiento de irregularidades del peso corporal, tales como obesidad, anorexia y caquexia utilizando el receptor 4 de lamelanocortina (MC4-R) como blanco para la intervencion. La invencion también se refiere a compuestos que modulan la actividado expresion del MC4-R, y el uso de tales compuestos en el tratamiento de irregularidades del peso corporal.
ARP970102540A 1996-06-10 1997-06-11 Metodos para seleccionar compuestos utiles en la regulacion del peso corporal AR013308A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/662,560 US5908609A (en) 1996-06-10 1996-06-10 Screening methods for compounds useful in the regulation of body weight
US08/780,749 US5932779A (en) 1996-06-10 1997-01-08 Screening methods for compounds useful in the regulation of body weight
US08/870,511 US6287763B1 (en) 1996-06-10 1997-06-06 Screening methods for compounds useful in the regulation of body weight

Publications (1)

Publication Number Publication Date
AR013308A1 true AR013308A1 (es) 2000-12-27

Family

ID=27418069

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102540A AR013308A1 (es) 1996-06-10 1997-06-11 Metodos para seleccionar compuestos utiles en la regulacion del peso corporal

Country Status (7)

Country Link
US (1) US6287763B1 (es)
EP (1) EP0915706B2 (es)
JP (1) JP2002514041A (es)
CN (1) CN1227496A (es)
AR (1) AR013308A1 (es)
AT (1) ATE446764T1 (es)
DK (1) DK0915706T3 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
AU2003221884A1 (en) * 2002-04-10 2003-10-27 Transtech Pharma, Inc. System and method for data analysis, manipulation, and visualization
US20060183789A1 (en) * 2002-09-25 2006-08-17 Lavanya Rajachandran Methods for preventing and treating obesity in patients with mc4 receptor mutations
WO2005059558A2 (en) * 2003-12-11 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc4 (mc4)
WO2005103689A1 (en) * 2004-04-27 2005-11-03 Galapagos Genomics N.V. Novel compounds for the treatment of alzheimer’s disease and methods for identifying same
WO2005103715A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
CA2621950A1 (en) * 2007-12-31 2009-06-30 University Of Basel Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor
AU2008200795A1 (en) * 2007-12-31 2009-07-16 University Of Basel Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339731C (en) * 1988-10-12 1998-03-17 Charles T. Caskey Multiplex genomic dna amplification for deletion detection
US5252724A (en) * 1990-05-17 1993-10-12 Sumitomo Electric Industries, Ltd. Method of extracting particular nucleic acid fragment
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5622860A (en) * 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors

Also Published As

Publication number Publication date
EP0915706B2 (en) 2012-09-26
EP0915706A1 (en) 1999-05-19
CN1227496A (zh) 1999-09-01
US6287763B1 (en) 2001-09-11
DK0915706T3 (da) 2010-02-01
EP0915706A4 (en) 2003-03-12
JP2002514041A (ja) 2002-05-14
EP0915706B1 (en) 2009-10-28
ATE446764T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
ES2043025T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene acido 3-(aminopropil)metil-fosfinico como agente terapeutico.
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
ATE252560T1 (de) Steroidrezeptor-modulator verbindungen und methoden
ECSP941122A (es) Derivados de 5-arilindoles
ES2056185T3 (es) Un procedimiento para la elaboracion de un sistema terapeutico a traves de la piel.
AR013308A1 (es) Metodos para seleccionar compuestos utiles en la regulacion del peso corporal
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
YU48607B (sh) Transdermalni terapeutski sistem (tts) za odavanje galantamina
UY24219A1 (es) Proteinas recombinantes obesas
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
ES2167571T3 (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
ATE306473T1 (de) Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
GT199700009AA (es) Terapia combinada para la osteoporosis
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
MX2024015502A (es) Anticuerpos variantes que se unen a los receptores de linfocitos t gamma-delta
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
ES2162493T3 (es) Metodo para el combate de la obesidad.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados